SavedAdd your journal

Journals / Journal of Experimental and Clinical Medicine / 2023 / Cilt: 40 Sayı: 2

Disease Severity and Serum Endocan Levels in Fibromyalgia Patients

Nevsun PIHTILI TAŞ
Pinar ÖNER
Rabia AYDOGAN BAYKARA
Özlem AYTAÇ
Feray Ferda ŞENOL
Pages
264–267
Publication Date
2023-07-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our study, in which we detected significantly higher endocan levels in patients with FMS compared to controls, supported the use of endocan as an important potential marker for FMS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We investigated the relationship between serum levels of endocan and disease activity in patients with Fibromyalgia.
📊
Key Findings & Data:Material method: Forty-five patients who met the 2010 ACR FMS criteria and 28 healthy controls were included in the study.
💡
Conclusion & Impact:Conclusion: Our study, in which we detected significantly higher endocan levels in patients with FMS compared to controls, supported the use of endocan as an important potential marker for FMS.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Fibromyalgia · Endocan · Symptom Severity Scale

Abstract

Objective: We investigated the relationship between serum levels of endocan and disease activity in patients with Fibromyalgia. Material method: Forty-five patients who met the 2010 ACR FMS criteria and 28 healthy controls were included in the study. To measure the severity of the disease in patients with fibromyalgia (FMS), the symptom severity scale (SSS), the widespread pain index (WPI), and the Visual Analogue Scale (VAS) were evaluated. Serum endocan, Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and CRP values of the patient and control groups were measured. Results: Patients with FMS had significantly higher serum endocan levels. Mean serum levels of endocan were 0.99 ± 0.28 ng/mL (range: 0.1-2.2) in patients with FMS and 0.63 ± 0.17) ng/mL (range: 0.4 ± 1.1) in control subjects (p <0.05). ROC analysis results for endocan level in the FMS group [AUC (%95 GA): 0.89 (0.81-0.97), sensitivity: %68.9, specificity: %96]. A significant correlation was found between endocan levels and SSS (r:0.33 p: 0.004). Conclusion: Our study, in which we detected significantly higher endocan levels in patients with FMS compared to controls, supported the use of endocan as an important potential marker for FMS.

🔖

Cite This Article

TAŞ, N. P., ÖNER, P., BAYKARA, R. A., AYTAÇ, Ö., ŞENOL, F. F. (2023). Disease Severity and Serum Endocan Levels in Fibromyalgia Patients. Journal of Experimental and Clinical Medicine, Cilt: 40 Sayı: 2, 264–267. https://ajindex.com/articles/966383

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bair M. J,Krebs E.E., Fibromyalgia, Ann. Intern. Med. 2020;172: ITC33. doi: 10.7326/AITC202003030
  2. Sarzi-Puttini P., Giorgi V, Marotto D., Atzeni F., Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat.Rev. Rheumatol. 2020; 16:645–660. doi: 10.1038/s41584-020-00506-w
  3. Ramírez-Tejero J. A.,. Martínez-Lara E,. Rus A, M. V. Camacho,. Del Moral M. L,Siles E.,Insight into the biological pathways underlying fibromyalgia by a proteomic approach,J. Proteomics 2018;186:47–55. doi: 10.1016/j.jprot.2018.07.009
  4. Qureshi A. G, Jha S. K, Iskander J, C Avanthika C, Jhaveri S, Hitendra V Pat et al.,Diagnostic Challenges and Management of Fibromyalgia, Cureus,2021. doi: 10.7759/cureus.18692
  5. Benlidayi I. C, Role of inflammation in the pathogenesis and treatment of fibromyalgia, Rheumatol. Int. 2019; 39:781–791. doi: 10.1007/s00296-019-04251-6
  6. Theoharides T. C., I. Tsilioni I. Bawazeer Mr Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. Front. Cell. Neurosci.2019;13 doi: 10.3389/fncel.2019.00353
  7. Rodriguez-Pintó I, Agmon-Levin N, Howard A.,Shoenfeld Y, Fibromyalgia and cytokines. Immunol. Lett.2014;161:200–203. doi: 10.1016/j.imlet.2014.01.009
  8. Uyar ME, Sezer S, Bal Z, Guliyev O, Tutal E, G. Genctoy G et alFibromyalgia and its Clinical Relevance in Renal Transplant Recipients. Transplant. Proc.2015;47:1105–1109. doi: 10.1016/j.transproceed.2015.01.026
  9. Lee J. H,. Cho K. I, Kim S. M., Lee H. G.,Kim T. I., Arterial Stiffness in Female Patients With Fibromyalgia and its Relationship to Chronic Emotional and Physical Stress. Korean Circ. J. 2011;41:596.doi: 10.4070/kcj.2011.41.10.596
  10. Scherpereel A, Gentina T, Grigoriu B, Sénéchal S, Janin A, Tsicopoulos, A et al. Overexpression of endocan induces tumor formation., Cancer Res.2003;63:6084–9. PMID:14522939
  11. Béchard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, et al. Endocan is a Novel Chondroitin Sulfate/Dermatan Sulfate Proteoglycan That Promotes Hepatocyte Growth Factor/Scatter Factor Mitogenic Activity.J. Biol. Chem. 2001; 276:48341–48349. doi: 10.1074/jbc.M108395200
  12. Nassef E. M, Elabd H. A., Mohamed Ali El Nagger B. M., Hala Mohamed Elzomor H.M, Kotb H. G., Sabry S et al.Serum Endocan Levels and Subclinical Atherosclerosis in Behçet’s SyndromeInt. J. Gen. Med.2022;15:6653–6659. doi: 10.2147/IJGM.S373863
  13. Kali A. and Shetty K. S. R., Endocan: A novel circulating proteoglycan. Indian J. Pharmacol. 2014; 46:579.